MAZE · Maze Therapeutics, Inc.
$27.69
-2.81% last session
End-of-day data · updated 2026-07-25
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-8.7
Dividend yield
—
Beta
—
Avg volume
1M
Employees
0K
2D change
-0.04%
5D change
-2.43%
10D change
-5.82%
30D change
2.44%
60D change
5.05%
MTD change
-7.15%
YTD change
-33.19%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MAZE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-14
Latest call per bank · past 12 months
JP Morgan
Overweight$58.00
+109.5% vs priceWells Fargo
Overweight$55.00
+98.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-14 | Truist Securities | Maintains | Buy | $68.00 → $64.00 |
| 2026-03-31 | JP Morgan | Maintains | Overweight | $52.00 → $58.00 |
| 2026-03-25 | BTIG | Reiterates | Buy | $46.00 |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy | $60.00 → $110 |
| 2026-03-18 | Truist Securities | Initiates | Buy | $0.00 → $68.00 |
| 2026-03-16 | Wedbush | Maintains | Outperform | $43.00 → $58.00 |
| 2026-03-10 | Mizuho | Initiates | Outperform | $0.00 → $97.00 |
| 2026-03-09 | BTIG | Reiterates | Buy | $46.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.6% above the 50-day MA ($26.99).
- Price vs 200-day MA: Trading 19.9% below the 200-day MA ($34.58).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.40) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($13.14) and high ($51.83).
MAZE Price Chart
Loading chart for MAZE…
Fundamentals
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.